Literature DB >> 14506054

Liposomal amphotericin B, and not amphotericin B deoxycholate, improves survival of diabetic mice infected with Rhizopus oryzae.

Ashraf S Ibrahim1, Valentina Avanessian, Brad Spellberg, John E Edwards.   

Abstract

The efficacies of liposomal amphotericin B (LAmB) and amphotericin B deoxycholate (AmB) were compared in a diabetic murine model of hematogenously disseminated Rhizopus oryzae infection. At 7.5 mg/kg of body weight twice a day (b.i.d.), LAmB significantly improved overall survival compared to the rates of survival in both untreated control mice (P = 0.001) and mice treated with 0.5 mg of AmB per kg b.i.d. (P = 0.047). These data indicate that high-dose LAmB is more effective than AmB in treating murine disseminated zygomycosis.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 14506054      PMCID： PMC201164          DOI： 10.1128/AAC.47.10.3343-3344.2003

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  10 in total

Review 1.  AmBisome: liposomal formulation, structure, mechanism of action and pre-clinical experience.

Authors:  Jill Adler-Moore; Richard T Proffitt
Journal:  J Antimicrob Chemother       Date:  2002-02       Impact factor: 5.790

Review 2.  Overview of the lipid formulations of amphotericin B.

Authors:  Bertrand Dupont
Journal:  J Antimicrob Chemother       Date:  2002-02       Impact factor: 5.790

3.  A case of chronic progressive rhinocerebral mucormycosis treated with liposomal amphotericin B and surgery.

Authors:  M Ericsson; M Anniko; H Gustafsson; C A Hjalt; R Stenling; A Tärnvik
Journal:  Clin Infect Dis       Date:  1993-04       Impact factor: 9.079

4.  Rhinocerebral mucormycosis treated with 32 gram liposomal amphotericin B and incomplete surgery: a case report.

Authors:  A A Cagatay; S S Oncü; S S Calangu; T T Yildirmak; H H Ozsüt; H H Eraksoy
Journal:  BMC Infect Dis       Date:  2001-11-23       Impact factor: 3.090

5.  Treatment of 21 cases of invasive mucormycosis with amphotericin B colloidal dispersion.

Authors:  R Herbrecht; V Letscher-Bru; R A Bowden; S Kusne; E J Anaissie; J R Graybill; G A Noskin; E Andrès; L A Pietrelli
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2001-07       Impact factor: 3.267

Review 6.  Zygomycetes in human disease.

Authors:  J A Ribes; C L Vanover-Sams; D J Baker
Journal:  Clin Microbiol Rev       Date:  2000-04       Impact factor: 26.132

7.  Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: maximum tolerated dose study.

Authors:  T J Walsh; J L Goodman; P Pappas; I Bekersky; D N Buell; M Roden; J Barrett; E J Anaissie
Journal:  Antimicrob Agents Chemother       Date:  2001-12       Impact factor: 5.191

Review 8.  Disseminated zygomycosis in a neutropenic patient: successful treatment with amphotericin B lipid complex and granulocyte colony-stimulating factor.

Authors:  C E Gonzalez; D R Couriel; T J Walsh
Journal:  Clin Infect Dis       Date:  1997-02       Impact factor: 9.079

9.  Specific susceptibility to mucormycosis in murine diabetes and bronchoalveolar macrophage defense against Rhizopus.

Authors:  A R Waldorf; N Ruderman; R D Diamond
Journal:  J Clin Invest       Date:  1984-07       Impact factor: 14.808

Review 10.  Mucormycosis (zygomycosis): is there news for the clinician?

Authors:  J R Boelaert
Journal:  J Infect       Date:  1994-05       Impact factor: 6.072
  10 in total
  38 in total

1.  The Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) study: a randomized, double-blinded, placebo-controlled trial.

Authors:  Brad Spellberg; Ashraf S Ibrahim; Peter V Chin-Hong; Dimitrios P Kontoyiannis; Michele I Morris; John R Perfect; David Fredricks; Eric P Brass
Journal:  J Antimicrob Chemother       Date:  2011-09-20       Impact factor: 5.790

2.  Combination therapy for mucormycosis: why, what, and how?

Authors:  Brad Spellberg; Ashraf Ibrahim; Emmanuel Roilides; Russel E Lewis; Olivier Lortholary; George Petrikkos; Dimitrios P Kontoyiannis; Thomas J Walsh
Journal:  Clin Infect Dis       Date:  2012-02       Impact factor: 9.079

3.  Comparison of the physicochemical, antifungal, and toxic properties of two liposomal amphotericin B products.

Authors:  Jon A Olson; Jill P Adler-Moore; Gerard M Jensen; Julie Schwartz; M Cecilia Dignani; Richard T Proffitt
Journal:  Antimicrob Agents Chemother       Date:  2007-10-29       Impact factor: 5.191

4.  Efficacy of liposomal amphotericin B and posaconazole in intratracheal models of murine mucormycosis.

Authors:  Guanpingsheng Luo; Teclegiorgis Gebremariam; Hongkyu Lee; Samuel W French; Nathan P Wiederhold; Thomas F Patterson; Scott G Filler; Ashraf S Ibrahim
Journal:  Antimicrob Agents Chemother       Date:  2013-05-06       Impact factor: 5.191

5.  Diabetic murine models for Acinetobacter baumannii infection.

Authors:  Guanpingsheng Luo; Brad Spellberg; Teclegiorgis Gebremariam; Michael Bolaris; Hongkyu Lee; Yue Fu; Samuel W French; Ashraf S Ibrahim
Journal:  J Antimicrob Chemother       Date:  2012-03-02       Impact factor: 5.790

6.  The endothelial cell receptor GRP78 is required for mucormycosis pathogenesis in diabetic mice.

Authors:  Mingfu Liu; Brad Spellberg; Quynh T Phan; Yue Fu; Yong Fu; Amy S Lee; John E Edwards; Scott G Filler; Ashraf S Ibrahim
Journal:  J Clin Invest       Date:  2010-05-17       Impact factor: 14.808

7.  PCR-Based Approach Targeting Mucorales-Specific Gene Family for Diagnosis of Mucormycosis.

Authors:  Clara Baldin; Sameh S M Soliman; Heewon H Jeon; Sondus Alkhazraji; Teclegiorgis Gebremariam; Yiyou Gu; Vincent M Bruno; Oliver A Cornely; Helen L Leather; Michele W Sugrue; John R Wingard; David A Stevens; John E Edwards; Ashraf S Ibrahim
Journal:  J Clin Microbiol       Date:  2018-09-25       Impact factor: 5.948

8.  CotH3 mediates fungal invasion of host cells during mucormycosis.

Authors:  Teclegiorgis Gebremariam; Mingfu Liu; Guanpingsheng Luo; Vincent Bruno; Quynh T Phan; Alan J Waring; John E Edwards; Scott G Filler; Michael R Yeaman; Ashraf S Ibrahim
Journal:  J Clin Invest       Date:  2013-12-20       Impact factor: 14.808

9.  Monotherapy or combination therapy of isavuconazole and micafungin for treating murine mucormycosis.

Authors:  Teclegiorgis Gebremariam; Nathan P Wiederhold; Abdullah Alqarihi; Priya Uppuluri; Nkechi Azie; John E Edwards; Ashraf S Ibrahim
Journal:  J Antimicrob Chemother       Date:  2016-10-24       Impact factor: 5.790

10.  Bacterial endosymbiosis is widely present among zygomycetes but does not contribute to the pathogenesis of mucormycosis.

Authors:  Ashraf S Ibrahim; Teclegiorgis Gebremariam; Mingfu Liu; Georgios Chamilos; Dimitrios Kontoyiannis; Richard Mink; Kyung J Kwon-Chung; Yue Fu; Christopher D Skory; John E Edwards; Brad Spellberg
Journal:  J Infect Dis       Date:  2008-10-01       Impact factor: 5.226
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.